VANCOMYCIN HYDROCHLORIDE CAPSULES, USP
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
22-11-2017
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE)
Fáanlegur frá:
FRESENIUS KABI CANADA LTD
ATC númer:
J01XA01
INN (Alþjóðlegt nafn):
VANCOMYCIN
Skammtar:
125MG
Lyfjaform:
CAPSULE
Samsetning:
VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) 125MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
20
Gerð lyfseðils:
Prescription
Lækningarsvæði:
GLYCOPEPTIDES
Vörulýsing:
Active ingredient group (AIG) number: 0131315002; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2021-11-30
Vara einkenni
_ _
_ _
_ _
Vancomycin Hydrochloride Capsules - Product Monograph
_ _
Page 1 of 24
PRODUCT MONOGRAPH
PR
VANCOMYCIN HYDROCHLORIDE CAPSULES, USP
vancomycin (as vancomycin hydrochloride)
125 mg and 250 mg
USP
Antibiotic
FRESENIUS KABI CANADA LTD.
Date of Revision:
165 Galaxy Blvd, Suite100 November 22, 2017
Toronto, ON, M9W 0C8
Submission Control No: 196466
_ _
_ _
_ _
Vancomycin Hydrochloride Capsules - Product Monograph
_ _
Page 2 of 24
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT
INFORMATION.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
6
DRUG INTERACTIONS
................................................................................................................
7
DOSAGE AND ADMINISTRATION
............................................................................................
7
OVERDOSAGE
...............................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
8
STORAGE AND STABILITY
........................................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................................ 9
PART II: SCIENTIFIC INFORMATION
....................................................................................
10
PH
Lestu allt skjalið
